Navigation Links
BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
Date:4/17/2008

SAN DIEGO, April 17 /PRNewswire/ -- BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today that it has initiated a Phase 2a clinical trial with its lead product candidate, BCI-540, for the treatment of depression with anxiety.

"We are encouraged by the enthusiasm expressed by our clinical investigators who view BCI-540 as a potential alternative to today's widely prescribed treatments for depression," noted Carrolee Barlow, M.D., Ph.D., Chief Scientific Officer at BCI. "Current therapies directly impact serotonin levels causing many unpleasant side effects, however we have shown that BCI-540 directly impacts neurogenesis without affecting serotonin levels. We are excited about the potential of this compound to change the way mood disorders are treated."

The twelve-week randomized double-blind, placebo-controlled study will evaluate safety, efficacy and tolerability of BCI-540 to determine whether 80 mg given once or three times daily is effective in the treatment of depression with anxiety versus placebo.

"BCI is utilizing our understanding of the power of neurogenesis coupled with our proprietary neurogenic platform technology to identify a strong portfolio of clinical candidates, such as BCI-540, that we plan to move into the clinic this year," said Jim Schoeneck, CEO at BCI. "Moving BCI-540 into the clinic is an important milestone and we are now actively enrolling patients and anticipate completing enrollment by the end of this year."

About BrainCells Inc.

BrainCells Inc. (BCI) is a San Diego-based drug discovery and development company that is applying its proprietary neurogenesis platform technology to identify and reposition compounds for the treatment of central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of CNS indications. For more information, visit http://www.braincellsinc.com.

Media Contact:

BrainCells Inc.

Kim Richards

Porter Novelli Life Sciences

619-849-5377

krichards@pnlifesciences.com


'/>"/>
SOURCE BrainCells Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
4. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
7. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
8. Metabolex Initiates Phase 1 Trial of MBX-2982
9. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
10. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 ... "Patient Handling Equipment Market by Product (Wheelchair, Scooters, ... Care (Bariatric Care, Critical Care, Wound), Accessories (Lifting, ... Forecast to 2021", published by MarketsandMarkets, the patient ... 17.18 Billion by 2021 at a CAGR of ...
(Date:5/23/2016)... Transparency Market Research has published ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... report, the exocrine pancreatic insufficiency market is anticipated to ... 2023 to reach US$2.85 Bn by 2023. ... the deficiency of the exocrine pancreatic enzymes, causing failure ...
(Date:5/23/2016)... , May 23, 2016 The World Health ... PrePex device to include adolescents aged 13 years, and ... can be offered for adult and adolescent males in the ... . PrePex was the first male circumcision device to ... MedTech,s CEO, Eddy Horowitz said: " The ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... seen a significant spike in their clients' employee participation for their wellness initiatives. ... screening by implementing a high-deductible health plan with outcome-based deductible incentives. As a ...
(Date:5/25/2016)... ... May 25, 2016 , ... Consumer access to organic foods and grower ... a maker of whole grain cereals and other plant-based foods, will introduce the first ... red winter wheat processed by Hesco/Dakota Organic Products. , The transitional designation means the ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... that it will join America's leading engineers at the American Society of Safety ... Georgia World Congress Center. , Engineers, speakers and exhibitors from more than ...
(Date:5/25/2016)... ... 25, 2016 , ... American Spine in Frederick, Maryland is ... surgeries in the Montgomery County, Howard County and Washington, D.C. areas, renowned spine ... American Spine every Monday. He will also perform surgeries in our Germantown surgical ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Sterling Global ... feature a unique and patented refillable hanging wipe dispenser. The campaign kick-off video is ... and will end June 25, 2016. The goal is to raise $1,000 per day ...
Breaking Medicine News(10 mins):